<DOC>
	<DOCNO>NCT02231489</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability JNJ-42756493 oral dose capsule ( reference ) versus tablet ( test ) healthy participant .</brief_summary>
	<brief_title>Study Assess Relative Bioavailability Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule Healthy Participants</brief_title>
	<detailed_description>This Phase 1 , randomize ( study drug assign chance ) , open-label ( people know identity intervention ) , 2 way crossover ( method use switch participant one study group change treatment group ) , single-dose study healthy participant . The study consist 3 phase : Screening Phase ( Day -21 Day -2 ) , Treatment Phase ( consist 2 single-dose treatment period , either JNJ-42756493 capsule JNJ-42756493 tablet ) Follow-up Phase ( 12-14 day last dose ) . All eligible participant randomly assign 1 2 treatment sequence ensure receive treatment , 1 period . Each treatment regimen separate washout period least 15 day . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Relative bioavailability two dosage form JNJ-42756493 ( test reference ) evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Participants receive thorough explanation optional pharmacogenomic research component study offer opportunity participate sign separate pharmacogenomic inform consent document Female participant must postmenopausal ( spontaneous menses least 2 year , surgically sterile must negative serum beta human chorionic gonadotropin ( hCG ) pregnancy test screen Male participant must agree use adequate contraception method deem appropriate investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Participant must body mass index ( BMI ) ( weight [ kilogram { kg } ] /height^2 [ m^2 ] ) 18 30 kg/m^2 ( inclusive ) , body weight less 50 kg Participants must nonsmoker least 6 month enter study Participants history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , metabolic bone disease , infection , illness investigator considers exclude participant could interfere interpretation study result Participants history current evidence ophthalmic disorder , central serous retinopathy retinal vein occlusion , active wet age relate macular degeneration , diabetic retinopathy macular edema , uncontrolled glaucoma , corneal pathology keratitis , keratoconjunctivitis , keratopathy , corneal abrasion , inflammation ulceration Participants use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol hormonal replacement therapy within 14 day first dose study drug schedule Participants positive test drug abuse , cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine , hallucinogen barbiturate screen Day1 first treatment period Participants clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center deem appropriate investigator . Retesting abnormal lab value may lead exclusion allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42756493</keyword>
	<keyword>JNJ-61818549</keyword>
</DOC>